To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure no-reply@cambridge.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Immunophenotyping of hematologic malignancies by flow cytometry is essential for establishing diagnosis. It is also an excellent tool for determining response to therapy. The chapter provides an up-to-date review of the basic principle of flow cytometry, immunophenotypic characterization of pediatric B- and T- lymphoblastic leukemia, mature B-cell leukemia/lymphoma, acute myeloid leukemia, and mixed phenotype acute leukemia. It discusses the principle of minimal residual disease detection including acquisition strategies, instrument and panels design, knowledge of the normal antigen maturation patterns, and immunophenotypic differential diagnosis of hematologic malignancies in children.
Precursor lymphoid neoplasms, encompassing lymphoblastic lymphoma/leukemias of B- and T-lineage are the most common type of childhood cancer. B-lymphoblastic neoplasms include >20 clinically significant molecular/genetic subtypes, which are relatively similar at the morphologic and immunophenotypic level. While the complex genetics of T-lymphoblastic neoplasms are well-characterized, they are not currently used for their pathologic subclassification. The overall cure rate of lymphoblastic neoplasms exceeds 90%, although outcome remains dismal for some disease subtypes. Effective treatment requires correct risk stratification (which involves disease features, particularly the genetic subtype, patient-specific features, including pharmacogenetics, and the level of residual disease in response to initial therapy), as well as minimal residual disease monitoring by various laboratory methods at specific timepoints during therapy. Therapy modalities include combination chemotherapy, tyrosine kinase inhibitors, monoclonal antibodies, and, for very high-risk, relapsed, or refractory disease, hematopoietic stem cell transplantation and chimeric antigen receptor T-cell therapies. This chapter will focus on the pathologic features of these neoplasms as they pertain to diagnosis, disease monitoring, and detection of relapse, in the context of modern diagnostic methodologies and therapy modalities.
Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL) are the two prototypical CD5-positive B-cell neoplasms. Both are characterized by CD5 expression, and distinguishing one from the other is essential when rendering a diagnosis. Therefore, these two entities are discussed together. The immunophenotype of typical and atypical CLL/SLL is described, along with minimal residual disease evaluation of CLL/SLL by flow cytometry. For MCL, the immunophenotype of the classic, leukemic non-nodal, and cyclin D1-negative subtypes is discussed. The differential diagnosis between CLL/SLL and MCL, as well as their distinction from reactive CD5+ B cells and other CD5+ B-cell lymphomas/leukemias, is also addressed.
In this chapter, we focus on the myelomonocytic lineage, discussing its normal and abnormal immunophenotypes. For minimal residual disease (MRD) evaluation, the primary focus is acute myeloid leukemia (AML); however, the similar principles apply to MRD evaluation for all other myeloid neoplasms, including myelodysplastic syndrome (MDS), myelodysplastic/myeloproliferative neoplasms (MDS/MPN), and myeloproliferative neoplasms (MPN). In our daily practice, similar flow cytometry panels are used for MRD evaluation across all myeloid neoplasms. Two approaches are used for MRD evaluation by flow cytometry: different from normal (DfN) and leukemia-associated immunophenotype (LAIP). This chapter covers both approaches. For DfN, we discuss in detail the characteristics of normal and abnormal immunophenotypes across three maturation stages: CD34+, CD34-CD117+, and monocytes. In combination with LAIP, immunophenotypic shifts and their associated mechanisms in AML are discussed. Panel design, gating strategies and reporting for flow cytometry MRD are also included.
This chapter introduces the classification of acute myeloid leukemia (AML) and highlights the importance of integrating both genetic and immunophenotypic findings in the diagnostic process. AML blasts exhibit a diverse range of immunophenotypic profiles, and key markers associated with each immunophenotypic subtype are discussed. The assessment of minimal residual disease (MRD) is crucial in AML, as it provides important information regarding treatment response and prognosis. Both flow cytometry and molecular testing are used in MRD evaluation.
This chapter covers the detailed immunophenotype of AML with CBFB rearrangement. We focus on CD34-positive myeloblasts and describe the expression status and intensity of key markers. The immunophenotypic features associated with different fusion transcripts are also highlighted. Minimal residual disease evaluation is discussed briefly.
Detection of minimal residual disease in ovarian tissue was carried out by histology, real-time quantitative polymerase chain reaction (RT-qPCR) and long-term xenografting. To avoid transferring malignant cells together with grafted ovarian tissue, ovarian follicles may be isolated from the surrounding tissue and then either cultured for in vitro follicle maturation or transplanted directly into the recipient. Transplantation of frozen-thawed isolated primordial follicles has been successfully carried out in mice, yielding normal offspring. After isolation and recovery of human follicles, the developmental capacity and viability of these isolated human follicles are evaluated after transplantation. New matrices have been developed based on hydrogels, foams or natural polymers which could be suitable to nestle the isolated follicles and form a kind of artificial ovary before grafting to the patient. This would allow patients at risk of ovarian metastasis to benefit also from ovarian tissue cryopreservation and transplantation.
Recommend this
Email your librarian or administrator to recommend adding this to your organisation's collection.